Clinical trials: Heart Failure With Reduced Ejection Fraction (HFrEF)
- Condition Heart Failure With Reduced Ejection Fraction (HFrEF)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Heart Failure
REALIsM-HF Pilot Study
The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart…
- Trial name
- REALIsM-HF (NCT03507439)
- Testing
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- Bayer
Acute Heart Failure
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following…
- Trial name
- PIONEER-HF (NCT02554890)
- Testing
- sacubitril/valsartan (LCZ696), Enalapril
- Where
- 123 sites in United States
- Volunteers
- 887 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Left Bundle-Branch Block
Mid-Q Response Study
The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study.
- Conditions
- Heart Failure, Left Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure NYHA Class II
- Trial name
- NCT04180696
- Testing
- aCRT ON, aCRT OFF
- Where
- 61 sites in Brunei, China and 8 more
- Volunteers
- 177 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Heart Failure With Reduced Ejection Fraction
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with LCZ696 in HFrEF patients following stabilization after an ADHF episode.
- Trial name
- TRANSITION (NCT02661217)
- Testing
- LCZ696
- Where
- 152 sites in Argentina, Belgium and 17 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Reduced Ejection Fraction
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.
- Trial name
- NCT02768298
- Testing
- LCZ696, Enalapril
- Where
- 34 sites in Germany
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Heart Failure and Reduced Ejection Fraction
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection…
- Trial name
- EVALUATE-HF (NCT02874794)
- Testing
- LCZ696 (sacubitril/valsartan), Enalapril
- Where
- 81 sites in United States
- Volunteers
- 465 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)
The purpose of this study was to generate effectiveness data of Angiotensin receptor neprilysin inhibitor (ARNI), in the Chinese Heart failure with reduced ejection fraction (HFrEF) patients with implantable cardioverted…
- Trial name
- RHYTHM (NCT04491136)
- Testing
- ACEI/ARB, ARNI
- Where
- 23 sites in China
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Sudden Cardiac Death, Sudden Cardiac Arrest
Heart Failure Optimization Study
This study is designed as a multi-center prospective observational study of newly diagnosed Heart Failure (HF) patients to test the hypothesis that additional Ejection Fraction (EF) recovery occurs between 90 and 180 days as…
- Conditions
- Sudden Cardiac Death, Sudden Cardiac Arrest, Heart Failure, Heart Failure Low Output
- Trial name
- HF-Opt (NCT03016754)
- Testing
- Wearable Cardioverter Defibrillator
- Where
- 67 sites in United States, Austria and 2 more
- Volunteers
- 602 people
- Sponsor
- Zoll Medical Corporation
Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had…
- Trial name
- VICTOR (NCT05093933)
- Testing
- Vericiguat
- Where
- 519 sites in United States, Argentina and 34 more
- Volunteers
- 6,106 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Reduced Ejection Fraction
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF…
- Trial name
- NCT04210375
- Testing
- JK07
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Salubris Biotherapeutics Inc